#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

#### VERTEX PHARMACEUTICALS INC / MA

Form 4

February 01, 2007

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to **SECURITIES** Section 16. Form 4 or

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction

(Print or Type Responses)

ALAM JOHN J

(Last)

1(b).

Form 5

obligations

1. Name and Address of Reporting Person \*

(First)

2. Issuer Name and Ticker or Trading

Symbol

VERTEX PHARMACEUTICALS INC / MA [VRTX]

(Month/Day/Year)

3. Date of Earliest Transaction

01/31/2007

5. Relationship of Reporting Person(s) to

Issuer

(Check all applicable)

**OMB APPROVAL** 

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Director 10% Owner Other (specify X\_ Officer (give title \_

EVP, Medicines Dev., & CMO

below)

C/O VERTEX **PHARMACEUTICALS** INCORPORATED, 130 WAVERLY

**STREET** 

(Street) 4. If Amendment, Date Original

(Middle)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

CAMBRIDGE, MA 01239

| (City)                               | (State)                                 | Zip) Table   | e I - Non-D  | erivative   | Secur            | ities Acqu  | iired, Disposed of   | f, or Beneficial   | y Owned   |
|--------------------------------------|---|--|--------------|---|------------------|-------------|--|--|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date<br>(Month/Day/Year) | Transaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year) |              | 4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5) |                  |             | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following | 6. Ownership<br>Form: Direct<br>(D) or<br>Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|                                      |   |  | Code V       | Amount  | (A)<br>or<br>(D) | Price       | Reported<br>Transaction(s)<br>(Instr. 3 and 4)                   |  |   |
| Common<br>Stock                      | 01/31/2007                              |  | M            | 1,000   | A                | \$<br>18.47 | 136,460  | D  |   |
| Common<br>Stock                      | 01/31/2007                              |  | M            | 500   | A                | \$ 9.07     | 136,960  | D  |   |
| Common<br>Stock                      | 01/31/2007                              |  | S <u>(1)</u> | 1,000   | D                | \$<br>35.46 | 135,960  | D  |   |
| Common<br>Stock                      | 01/31/2007                              |  | S <u>(1)</u> | 500   | D                | \$<br>35.46 | 135,460  | D  |   |

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock

6,265

Ι

401(k)

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transactic<br>Code<br>(Instr. 8) | 5. Number out of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |  |
|---|---|---|---|--|---|--|--------------------|---|--|
|   |   |   |   | Code V                                 | (A) (D)   | Date Exercisable   | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |
| Stock<br>Options                                    | \$ 18.47  | 01/31/2007                              |   | M                                      | 1,000   | (2)  | 09/25/2007         | Common<br>Stock   | 1,000                                  |
| Stock<br>Options                                    | \$ 9.07   | 01/31/2007                              |   | M                                      | 500   | 03/11/2004(3)  | 12/10/2013         | Common<br>Stock   | 500                                    |

## **Reporting Owners**

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

ALAM JOHN J C/O VERTEX PHARMACEUTICALS **INCORPORATED** 130 WAVERLY STREET CAMBRIDGE, MA 01239

EVP, Medicines Dev., & **CMO** 

### **Signatures**

Valerie L. Andrews, Attorney-In-Fact

02/01/2007

\*\*Signature of Reporting Person

Date

Reporting Owners 2

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Dr. Alam's company approved trading plan established under rule 10b5-1.
- (2) Fully exercisable.
- (3) Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years from 12/11/2003.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.